Original document(17 pages)  中文版
    The invention relates to medicament preparations for transdermal application used in the treatment of Parkinson's disease. Said preparations contain a combination of at least two active ingredients, selected from the following groups of active ingredients: dopamine agonists and L-dopa, monoaminoxidase inhibitors, anticholinergics, NMDA receptor antagonists and sympathomimetics, whereby at least two of the active ingredients belong to different active ingredient groups.
Application Number
申请号
200480022549 Application Date
申请日
2004.08.14
Title 名称 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
Publication Number
公开号
1832732 Publication Date
公开日
2006.09.13
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K9/70,A61K45/06,A61K31/13,A61K31/428,A61K31/381,A61P25/16
Applicant(s) Name
申请人
Lohmann Therapie Syst Lts
Address 地址
Inventor(s) Name 发明人 Horstmann Michael
Attorney & Agent 代理人 nan ting zhu mei

  
Inhaler for basic pharmaceutical agents and method for production thereof
Non-reclosable packaging for products that are hazardous to health, and method for the production thereof
Deramciclane-fumarate tablets
Substituted 2-amino-1,2,3,4-tetrahydronaphthalene of depression
New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith
Stable sustained release oral dosage form of gabapentin
Mixed zeaxanthin ester concentrate and uses thereof
Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
Indol-5 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.